PROTOKOLwiki
COMPOUNDS / PEPTIDE / THYMOSIN ALPHA-1
PEPTIDE

THYMOSIN ALPHA-1

LOW RISK
BEST FOR:Immune Support●●●●●●●○○○7/10
THYMOSIN ALPHA-1 · TΑ1 · TA1 · THYMALFASIN · ZADAXIN · THYMOSIN Α1
PeptideImmunomodulatorThymic HormoneImmune SupportAntiviral

Thymic peptide hormone that modulates immune function by enhancing T-cell differentiation and activity.

ROUTE / DOSAGE
LOW0.8mg
STANDARD1.6mg
HIGH3.2mg
Note: Primary clinical route; 1.6mg SC twice weekly for hepatitis B/C
CYCLE
2x per week for immune indications treatment courses typically 6-12 months
BIOAVAILABILITY
Well absorbed subcutaneously peak serum within 2 hours
ACTIVE DURATION
~24 hours (subjective)
STORAGE
Refrigerate at 2-8°C protect from light reconstituted solution stable for 24 hours
HALF-LIFE
~2 hours (plasma)
DURATION BREAKDOWN
Total24 hours
Onset1-2 hours
Come up1-2 hours
Peak2-4 hours
Offset4-8 hours
After effects12-24 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Enhanced T-cell differentiation and activity
Increased CD4+ T-cell counts
Improved CD4+/CD8+ ratio
Reduced inflammatory markers (CRP)
Enhanced vaccine response
Improved immune homeostasis
Reduced secondary infection rates
§ 02 — RISKS
Local injection site irritation (most common adverse effect)
Potential immune stimulation in autoimmune conditions
Limited safety data for long-term use in healthy individuals
Theoretical risk of immune overstimulation with concurrent immunomodulatory drugs
Lack of FDA approval means quality control varies for non-pharmaceutical sources
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Clinical trials have evaluated Tα1 primarily in hepatitis B and C, where it showed mixed results as monotherapy for HBV and promising efficacy combined with interferon for HCV. Meta-analyses demonstrate significant reductions in mortality among sepsis and moderate-to-severe COVID-19 patients treated with Tα1. A large meta-analysis of 39 RCTs (3,329 patients) showed improved pulmonary function and immune markers in COPD exacerbation patients. Studies in HIV-1 suggest potential for immune reconstitution beyond antiretroviral therapy alone. However, many trials are small, heterogeneous, and conducted primarily in China; large-scale Western RCTs are lacking. Evidence for anti-aging applications remains preclinical.

§ 06 — SOURCES
[1]
Thymosin alpha-1 - Pharmacology, pharmacokinetics, clinical efficacy
pubmed.ncbi.nlm.nih.gov ↗
[2]
Aging and Thymosin Alpha-1
pubmed.ncbi.nlm.nih.gov ↗
[3]
Thymosin alpha 1 treatment for patients with sepsis
pubmed.ncbi.nlm.nih.gov ↗
[4]
Thymosin Alpha 1 Plus Routine Treatment for AECOPD: Systematic Review and Meta-Analysis
pubmed.ncbi.nlm.nih.gov ↗
[5]
Serum thymosin alpha 1 levels in normal and pathological conditions
pubmed.ncbi.nlm.nih.gov ↗
[6]
Thymosin alpha 1 alleviates inflammation in severe acute pancreatitis: systematic review and meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[7]
Thymosin alpha 1 and HIV-1: recent advances and future perspectives
pubmed.ncbi.nlm.nih.gov ↗
[8]
Efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: systematic review and meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT